NCT07082868

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

A Phase Ib Trial With Dose Expansion of Epcoritamab in Combination With Ibrutinib in Refractory/Recurrent CNS Lymphoma (EIFEL-Trial)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out whether the combination of epcoritamab and ibrutinib is a safe treatment approach that causes few or mild side effects in people with relapsed/refractory primary central nervous system lymphoma (PCNSL) or secondary central nervous system lymphoma (SCNSL).

Conditions

• Primary Central Nervous System Lymphoma (PCNSL)
• Primary Central Nervous System Lymphoma
• Relapsed Primary Central Nervous System Lymphoma
• Refractory Primary Central Nervous System Lymphoma
• Central Nervous System Lymphoma
• Secondary Central Nervous System Lymphoma
• Secondary Central Nervous System Lymphoma (SCNSL)

Interventions

Type	Name	Description
DRUG	ibrutinib	Ibrutinib should be self-administered daily by the participant and should be taken at approximately the same time each day
DRUG	Epcoritamab	Epcoritamab will be administered at the study site clinic, as a SC injection

Timeline

• Start date: 2025-08-13
• Primary completion: 2028-08-01
• Completion: 2028-08-01
• First posted: 2025-07-24
• Last updated: 2026-02-17

Locations

8 sites across 1 country: United States

Regulatory

• FDA-regulated drug study